Marshall Wace, LLP Dyne Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
A detailed history of Marshall Wace, LLP transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 53,705 shares of DYN stock, worth $1.85 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,705Holding current value
$1.85 Million% of portfolio
0.0%Shares
7 transactions
Others Institutions Holding DYN
# of Institutions
176Shares Held
87.1MCall Options Held
130KPut Options Held
209K-
Atlas Venture Life Science Advisors, LLC8.02MShares$276 Million28.49% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$270 Million31.49% of portfolio
-
Black Rock Inc. New York, NY5.39MShares$185 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.56MShares$157 Million4.27% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.25MShares$146 Million0.02% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.78B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...